1. Home
  2. Clinical Topics
  3. Cardio-Pulmonary
  4. FDA drops certain restrictive requirements for Nplate and Promacta
Cardio-PulmonaryClinical TopicsDrugs and DevicesHealthcare & TechnologyNewsWeb Exclusives

FDA drops certain restrictive requirements for Nplate and Promacta


The U.S. Food and Drug Administration has announced changes to the Risk Evaluation and Mitigation Strategies for Nplate (romiplostim) and Promacta (eltrombopag). Among the changes: Healthcare professionals are no longer required to complete periodic safety forms for patients either drug. In addition, healthcare professionals, hospitals, specialty care facilities, and patients are no longer required to be enrolled in the Nplate NEXUS (Network of Experts Understanding and Supporting Nplate and Patients) Program or the Promacta CARES Program to prescribe, dispense or receive the drugs. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts